Treatment Patterns and Outcomes with Luspatercept in Patients with Lower-risk Myelodysplastic Syndromes: A Retrospective US Cohort Analysis
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Malcovati L, Della Porta M, Strupp C, Ambaglio I, Kuendgen A, Nachtkamp K
. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica. 2011; 96(10):1433-40.
PMC: 3186303.
DOI: 10.3324/haematol.2011.044602.
View
2.
de Swart L, Smith A, Johnston T, Haase D, Droste J, Fenaux P
. Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry. Br J Haematol. 2015; 170(3):372-83.
DOI: 10.1111/bjh.13450.
View
3.
Platzbecker U, Della Porta M, Santini V, Zeidan A, Komrokji R, Shortt J
. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial. Lancet. 2023; 402(10399):373-385.
DOI: 10.1016/S0140-6736(23)00874-7.
View
4.
Zeidan A, Salimi T, Epstein R
. Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials?. Future Oncol. 2021; 17(36):5163-5175.
DOI: 10.2217/fon-2021-0936.
View
5.
Duetz C, Cucchi D, Polak T, Janssen J, Ossenkoppele G, Estey E
. The wider perspective: twenty years of clinical trials in myelodysplastic syndromes. Br J Haematol. 2021; 196(2):329-335.
DOI: 10.1111/bjh.17892.
View